Scientific Reports (Apr 2023)

Circulating proteins to predict COVID-19 severity

  • Chen-Yang Su,
  • Sirui Zhou,
  • Edgar Gonzalez-Kozlova,
  • Guillaume Butler-Laporte,
  • Elsa Brunet-Ratnasingham,
  • Tomoko Nakanishi,
  • Wonseok Jeon,
  • David R. Morrison,
  • Laetitia Laurent,
  • Jonathan Afilalo,
  • Marc Afilalo,
  • Danielle Henry,
  • Yiheng Chen,
  • Julia Carrasco-Zanini,
  • Yossi Farjoun,
  • Maik Pietzner,
  • Nofar Kimchi,
  • Zaman Afrasiabi,
  • Nardin Rezk,
  • Meriem Bouab,
  • Louis Petitjean,
  • Charlotte Guzman,
  • Xiaoqing Xue,
  • Chris Tselios,
  • Branka Vulesevic,
  • Olumide Adeleye,
  • Tala Abdullah,
  • Noor Almamlouk,
  • Yara Moussa,
  • Chantal DeLuca,
  • Naomi Duggan,
  • Erwin Schurr,
  • Nathalie Brassard,
  • Madeleine Durand,
  • Diane Marie Del Valle,
  • Ryan Thompson,
  • Mario A. Cedillo,
  • Eric Schadt,
  • Kai Nie,
  • Nicole W. Simons,
  • Konstantinos Mouskas,
  • Nicolas Zaki,
  • Manishkumar Patel,
  • Hui Xie,
  • Jocelyn Harris,
  • Robert Marvin,
  • Esther Cheng,
  • Kevin Tuballes,
  • Kimberly Argueta,
  • Ieisha Scott,
  • The Mount Sinai COVID-19 Biobank Team,
  • Celia M. T. Greenwood,
  • Clare Paterson,
  • Michael A. Hinterberg,
  • Claudia Langenberg,
  • Vincenzo Forgetta,
  • Joelle Pineau,
  • Vincent Mooser,
  • Thomas Marron,
  • Noam D. Beckmann,
  • Seunghee Kim-schulze,
  • Alexander W. Charney,
  • Sacha Gnjatic,
  • Daniel E. Kaufmann,
  • Miriam Merad,
  • J. Brent Richards

DOI
https://doi.org/10.1038/s41598-023-31850-y
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Predicting COVID-19 severity is difficult, and the biological pathways involved are not fully understood. To approach this problem, we measured 4701 circulating human protein abundances in two independent cohorts totaling 986 individuals. We then trained prediction models including protein abundances and clinical risk factors to predict COVID-19 severity in 417 subjects and tested these models in a separate cohort of 569 individuals. For severe COVID-19, a baseline model including age and sex provided an area under the receiver operator curve (AUC) of 65% in the test cohort. Selecting 92 proteins from the 4701 unique protein abundances improved the AUC to 88% in the training cohort, which remained relatively stable in the testing cohort at 86%, suggesting good generalizability. Proteins selected from different COVID-19 severity were enriched for cytokine and cytokine receptors, but more than half of the enriched pathways were not immune-related. Taken together, these findings suggest that circulating proteins measured at early stages of disease progression are reasonably accurate predictors of COVID-19 severity. Further research is needed to understand how to incorporate protein measurement into clinical care.